Introduction
============

Depression is a common psychiatric disorder characterized by a number of signs and symptoms which may include depressed mood, anhedonia, insomnia, anorexia, difficulty in concentration, and suicidal thought. The lifetime prevalence of the condition in the general population is reported to be 10%--15%, but in women has been reported to be up to 25%.[@b1-cpaa-4-001]--[@b3-cpaa-4-001] Depression is much more common in women, occurring in a ratio of 2:1, and is the leading cause of disease-related disability in women.[@b4-cpaa-4-001],[@b5-cpaa-4-001] Mental health patterns in Iran are similar to those in other countries, but it seems that the prevalence of mental health disorders in Iran is lower than reported elsewhere. A review of the literature shows a prevalence rate for depression of 4.29% in Iran.[@b6-cpaa-4-001],[@b7-cpaa-4-001]

Treatment of depression includes pharmacotherapy and psychotherapy. The common antidepressant drugs are tricyclic antidepressants, heterocyclic antidepressants, monoamine oxidase inhibitors, selective serotonin reuptake inhibitors (SSRIs), and sympathomimetics.[@b8-cpaa-4-001],[@b9-cpaa-4-001] The side effects of SSRI are reported to be nausea, headache, anger, weight loss, insomnia, yawning, diarrhea, weakness, fatigue, and dyspepsia. The side effects reported for tricyclic antidepressants include drowsiness, anticholinergic effects, weight gain, hypotension, tiredness, dullness, and tachycardia. Among the tricyclic antidepressants, nortriptyline is said to have the fewest complications. Fluoxetine was the first of the SSRIs to be introduced onto the US market and remains the most commonly used antidepressant agent in the US.[@b10-cpaa-4-001]--[@b13-cpaa-4-001]

There are some controversies about the effectiveness of nortriptyline and fluoxetine in the treatment of depression. While some studies have shown that nortriptyline is more effective than fluoxetine,[@b13-cpaa-4-001]--[@b16-cpaa-4-001] others have shown fluoxetine to be more effective than nortriptyline.[@b12-cpaa-4-001],[@b17-cpaa-4-001],[@b18-cpaa-4-001] On the other hand, some studies have shown that there was no significant difference between the two drugs,[@b19-cpaa-4-001]--[@b21-cpaa-4-001] although some researchers believe that there is a significant difference between the two drugs depending on age and gender.[@b22-cpaa-4-001] SSRIs are believed to be better tolerated and to have a better safety profile than the tricyclic antidepressants.[@b20-cpaa-4-001],[@b23-cpaa-4-001],[@b24-cpaa-4-001] The aim of this study was to compare the efficacy and patient satisfaction profile for nortriptyline with that of fluoxetine in the treatment of major depressive disorder and to determine the influence of related factors, including gender, age, and educational level, on outcome.

Materials and methods
=====================

This study was a randomized, double-blind, clinical trial with a 6-month follow-up period carried out in 120 patients referred to the Shahid Mofatteh Psychiatric Clinic, Yasuj, Iran, from 2007 to 2008. The patients were selected by convenience sampling and randomized to one of two treatment groups. Twenty-three participants did not complete the study as a result of lack of cooperation, not taking the drugs regularly, and lack of punctuality. Inclusion criteria were being aged 15--60 years and a diagnosis of major depressive disorder on the basis of an interview and the Beck depression rating scale. Patients were excluded if they had received any antidepressant drug previously, had criteria for grief, adjustment disorder, major depressive disorder with psychotic features, had concomitant axis II or III disorder, a history of bipolar disorder, or schizophrenia. Women were excluded if they were pregnant or breast-feeding. Patients who did not respond to the drugs within 8 weeks were also excluded. This research was approved by the ethics committee and vice chancellor for research at Yasuj University of Medical Sciences. Patients were informed about the survey, and written consent was obtained from all participants or their legal guardians.

The study data were gathered from interviews with participants at the beginning of the study, and by clinical examination and using the Beck depression rating scale at the beginning, middle, and end of the study. The Beck depression inventory was used because it has been localized and validated for Iran. It also has appropriate reliability and validity.[@b25-cpaa-4-001],[@b26-cpaa-4-001] Both patients and the evaluating team were unaware of treatment allocation.

The patients received nortriptyline or fluoxetine treatment for 6 months. At the end of trial, 23 patients had withdrawn and 97 had remained. For the Beck depression inventory, a score \>10 was considered to be depression, with 10--19 scored as mild, 20--29 as moderate, 30--39 as partially severe, and \>40 as severe depression.[@b27-cpaa-4-001],[@b28-cpaa-4-001] All participants had a score ≥30 (severe depression). Nortriptyline up to 150 mg/day or fluoxetine up to 60 mg/day was used for 6 months according to the severity of depression. Another self-developed questionnaire was used to record the age, gender, and educational level of the participants. Educational level was divided into four groups, ie, illiterate, primary school, high school, and university graduate. For illiterate cases, the questions were read out verbally and a complete verbal explanation was given.

A questionnaire was developed to measure the patient's satisfaction with their trial medication and any side effects. It consisted of 11 items measured on a three-point Likert scale (1 = unsatisfied, 2 = fairly satisfied, 3 = satisfied). The reliability of the instruments was measured using Cronbach's alpha. The reliability index was good at 8.41. Drug side effects were also recorded.

Statistical analysis
--------------------

The paired *t*-test was used to compare mean Beck test scores for each group before and after treatment. The independent *t*-test was used to compare the means of the two groups at baseline, and at 3-month and 6-month follow-up. Paired *t*-tests were used to compare mean depression scores at the beginning of treatment with those at the 3-month and 6-month follow-up. The total score for satisfaction in terms of side effects and treatment outcome was estimated, and using cut-off points of 40 and 60 was converted into qualitative scores of satisfied, partially satisfied, and unsatisfied. Fisher's Exact test was then used to calculate the total satisfaction scores for the two treatment groups. The results are presented as the mean ± standard deviation, and the significance level was set at *P* \< 0.05.

Results
=======

There were approximately equal numbers of men and women in both treatment groups, and the mean age was 35 years ([Table 1](#t1-cpaa-4-001){ref-type="table"}). [Tables 2](#t2-cpaa-4-001){ref-type="table"}--[4](#t4-cpaa-4-001){ref-type="table"} show that there was no significant difference between the two groups with regard to basic demographic data including age, gender, and educational level. The results also indicate that there was no significant difference between the two groups for mean Beck depression test scores before intervention. However, there was a significant difference for these scores between the groups after 3 and 6 months of treatment ([Table 5](#t5-cpaa-4-001){ref-type="table"}). Both drugs were effective in major depression at 3 and 6 months of follow-up, but fluoxetine was more effective than nortriptyline ([Figure 1](#f1-cpaa-4-001){ref-type="fig"}). The results also indicate that there was a significant difference between the groups for mean Beck depression score before and after 3 and 6 months of treatment (*P* \< 0.05, [Table 5](#t5-cpaa-4-001){ref-type="table"}). The descriptive statistics shown in [Table 5](#t5-cpaa-4-001){ref-type="table"} indicate that the changes in mean Beck depression score at the end of the study compared with baseline was 16.96 ± 4.96 and 13.14 ± 4.68 for fluoxetine and nortriptyline, respectively.

Both drugs had side effects, including headache, drowsiness, constipation, anorexia, nausea, and vomiting. Fluoxetine was significantly correlated with nausea while nortriptyline was not. Nortriptyline was significantly correlated with headache, dizziness, drowsiness, weakness, aggression, and constipation ([Table 6](#t6-cpaa-4-001){ref-type="table"}). Total satisfaction with the drugs was estimated by patient perception of side effects, and the outcomes were compared between the two groups. The results indicated the patients were more satisfied with fluoxetine than with nortriptyline ([Table 7](#t7-cpaa-4-001){ref-type="table"}).

Discussion
==========

Depression is a common psychiatric disorder which may cause depressed mood, anhedonia, insomnia, anorexia, difficulty in concentration, and suicidal thought. It can be treated by both psychotherapy and pharmacotherapy. Tricyclic antidepressants and SSRIs are drugs commonly used in the treatment of depression. This study compared the efficacy of nortriptyline (a tricyclic antidepressant) and fluoxetine (an SSRI) in the treatment of patients with major depressive disorder. Its findings suggest that both nortriptyline and fluoxetine were effective, which is in agreement with other studies. However, fluoxetine was more effective than nortriptyline in the treatment of major depressive disorder, and age, gender, and educational level of the patients did not have a significant impact on the treatment.

Our results are different from those of previous studies reported by Fabre et al, Roose et al, Akhondzadeh et al, and Robinson et al.[@b13-cpaa-4-001]--[@b16-cpaa-4-001] These reported that nortriptyline was more effective than fluoxetine. Roose et al also reported that nortriptyline was more effective than fluoxetine in depression with melancholic features. Our results are also different in this respect from the studies reported by Anderson et al, Finkel et al, and Song et al, [@b19-cpaa-4-001]--[@b21-cpaa-4-001] Further, unlike Joyce et al, who reported that older male melancholic patients had a markedly superior response to nortriptyline compared with fluoxetine, and that young female melancholic patients had a markedly superior response to fluoxetine,[@b22-cpaa-4-001] the results of our study showed that fluoxetine is more effective than nortriptyline but with no effect of age and gender.

However, the results of our study are similar to those of Khade et al, Attari et al, Bhurghri et al, and Anderson et al.[@b12-cpaa-4-001],[@b17-cpaa-4-001]--[@b19-cpaa-4-001] In our study, fluoxetine was compared with nortriptyline, but in the study by Khade et al nortriptyline was compared with fluvoxamine (an SSRI), and fluvoxamine was reported to be better than nortriptyline.[@b12-cpaa-4-001]

In terms of toxicity, it could be argued that both drugs had some side effects. In our study fluoxetine was associated with nausea, similar to other studies.[@b10-cpaa-4-001]--[@b13-cpaa-4-001],[@b23-cpaa-4-001],[@b24-cpaa-4-001] Meanwhile, Khade et al and Otsubo et al reported that fluvoxamine was associated with nausea and Uher et al reported that escitalopram was associated with insomnia, diarrhea, and yawning.[@b10-cpaa-4-001],[@b12-cpaa-4-001],[@b24-cpaa-4-001] In our study, fluoxetine was significantly associated with nausea, whereas Bhurghri et al reported that nortriptyline was significantly associated with nausea and headache.[@b18-cpaa-4-001] Our results indicate that nortriptyline was not significantly associated with dry mouth, but other studies have found this relationship. In our study, nortriptyline was significantly associated with headache, dizziness, constipation, drowsiness, weakness, and aggression, which seems to be in line with other studies.[@b10-cpaa-4-001]--[@b13-cpaa-4-001],[@b23-cpaa-4-001],[@b24-cpaa-4-001] Khade et al reported that drowsiness, tiredness, and dullness were related to this drug, and Uher et al further reported that dry mouth, constipation, and weight gain were associated with nortriptyline.[@b10-cpaa-4-001],[@b12-cpaa-4-001]

Based on the results of our study, which are consistent with those of Finkel et al, Kasper et al, and Otsubo et al,[@b20-cpaa-4-001],[@b23-cpaa-4-001],[@b24-cpaa-4-001] it could be argued that the patient satisfaction and tolerability profiles of fluoxetine are better than those of nortriptyline ([Table 7](#t7-cpaa-4-001){ref-type="table"}). Finally, we can conclude that fluoxetine and nortriptyline are effective in major depressive disorder, but that fluoxetine was more effective than nortriptyline, and age, gender, and educational level did not contribute to the efficacy profiles of these drugs.
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###### 

Baseline data for fluoxetine and nortriptyline groups

                                              Nortriptyline group   Fluoxetine group
  ------------------------------------------- --------------------- ------------------
  Female                                      25                    26
  Male                                        24                    22
  Age (mean ± standard deviation)             34.5 ± 15.50          35.1 ± 14.80
  Mean depression score before intervention   32.85 ± 6.23          33.12 ± 6.50

###### 

Comparison of mean Beck depression scores according to age before and after 3 and 6 months of treatment with fluoxetine or nortriptyline

  Age, years   n    Nortriptyline   n              Fluoxetine                                         
  ------------ ---- --------------- -------------- -------------- ---- --------------- -------------- --------------
  \<20         6    31.83 ± 2.11    24.12 ± 3.67   19.30 ± 2.01   5    32.60 ± 2.8 1   19.60 ± 1.96   15.40 ± 2.05
  20--30       22   33.40 ± 4.92    23.18 ± 4.10   19.72 ± 4.31   25   33.32 ± 4.21    19.04 ± 3.30   16.20 ± 4.11
  30--40       14   32.21 ± 3.83    23.22 ± 3.78   19.50 ± 3.12   12   33.08 ± 3.90    19.91 ± 2.15   16.30 ± 3.27
  \>40         7    32.31 ± 2.95    23.42 ± 2.90   19.85 ± 1.78   6    32.33 ± 3.01    19.10 ± 1.98   15.60 ± 3.94
  All ages     49   32.85 ± 6.23    23.65 ± 4.48   19.71 ± 4.21   48   33.12 ± 6.50    19.37 ± 3.96   16.16 ± 4.02

**Note:** Analysis of variance *P* \> 0.05.

###### 

Comparison of mean Beck depression scores according to gender before and after 3 and 6 months of treatment with fluoxetine or nortriptyline

  Gender      n    Nortriptyline   n              Fluoxetine                                        
  ----------- ---- --------------- -------------- -------------- ---- -------------- -------------- --------------
  Female      25   33.05 ± 6.68    24.43 ± 5.21   19.90 ± 4.40   26   32.70 ± 6.93   18.93 ± 4.11   16.34 ± 5.01
  Male        24   32.63 ± 5.00    23.30 ± 4.17   19.56 ± 3.35   22   33.40 ± 5.81   19.41 ± 3.24   15.90 ± 3.49
  All level   49   32.85 ± 6.23    23.65 ± 4.48   19.71 ± 4.21   48   33.12 ± 6.5    19.37 ± 3.96   16.16 ± 4.02

###### 

Comparison of mean Beck depression scores based on educational level before and after 3 and 6 months of treatment with fluoxetine or nortriptyline

  Educational level   n    Nortriptyline   n              Fluoxetine                                        
  ------------------- ---- --------------- -------------- -------------- ---- -------------- -------------- --------------
  Not educated        21   33.10 ± 6.99    24.10 ± 4.21   19.90 ± 4.40   20   32.65 ± 2.93   19.03 ± 3.11   16.24 ± 4.01
  Low educated        16   32.80 ± 5.00    23.50 ± 4.67   19.06 ± 4.35   17   33.40 ± 2.91   19.91 ± 4.34   15.90 ± 4.29
  High educated       12   32.33 ± 5.76    23.31 ± 4.24   19.52 ± 3.97   11   32.90 ± 2.45   19.80 ± 3.99   16.02 ± 3.98
  All levels          49   32.85 ± 6.23    23.65 ± 4.48   19.71 ± 4.21   48   33.12 ± 6.50   19.37 ± 3.96   16.16 ± 4.02

###### 

Mean Beck scores for depressed patients referring to Yasuj Psychiatric Clinic, Iran, by time and kind of treatment

                            Month 0                                                     Month 3        Month 6        Total decrease after 6 months
  ------------------------- ----------------------------------------------------------- -------------- -------------- -------------------------------
  Nortriptyline             32.85 ± 6.23[\*\*](#tfn3-cpaa-4-001){ref-type="table-fn"}   23.65 ± 4.48   19.71 ± 4.21   13.14 ± 4.68
  Fluoxetine                33.12 ± 6.50                                                19.37 ± 3.96   16.16 ± 4.02   16.96 ± 4.96
  Significance (*t*-test)   *P* \> 0.05                                                 *P* \< 0.05    *P* \< 0.05    --

**Note:**

Mean ± standard deviation.

###### 

Mean percent frequency of treatment-emergent adverse events

                                             Significance (χ^2^ test)
  ------------------ ----------- ----------- --------------------------
  Headache           24 (48.9)   17 (35.4)   0.026
  Dizziness          18 (36.7)   8 (16.3)    0.018
  Constipation       13 (26.5)   2 (4.2)     0.016
  Drowsiness         15 (30.6)   4 (8.3)     0.005
  Weakness           25 (51.0)   11 (22.9)   0.01
  Dry mouth          1 (2.1)     3 (6.3)     0.17
  Aggression         25 (51.0)   4 (8.3)     0.001
  Hypersomnia        14 (28.6)   12 (25.0)   0.39
  Nausea, vomiting   0 (0)       17 (35.4)   0.045
  Anorexia           16 (33.3)   17 (35.4)   0.45

**Note:** All numbers are written as frequency (%).

###### 

Satisfaction profile for nortriptyline and fluoxetine in depressed patients referred to Yasuj Psychiatry Clinic, Iran

  Satisfaction    Dissatisfied   Partially satisfied   Satisfied    Total
  --------------- -------------- --------------------- ------------ ----------
  **Drug**                                                          
  Nortriptyline   9 (18.4)       33 (67.3)             7 (14.3)     49 (100)
  Fluoxetine      5 (10.4)       22 (45.8)             21 (43.75)   48 (100)

**Notes:** χ^2^ = 15.2; DF = 3; *P* \< 0.012; all numbers are written as frequency (%).
